

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX, INC. AND APOTEX, CORP.,
Petitioners

v.

CELGENE CORPORATION,
Patent Owner

Case IPR2018-00685
Patent 8,741,929 B2
Issued: June 3, 2014

Title: METHODS USING 3-(4-AMINO-1-OXO-1,3-DIHYDRO-
ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE
FOR TREATMENT OF MANTLE CELL LYMPHOMAS

DECLARATION OF MICHAEL J. THIRMAN, M.D.

TABLE OF CONTENTS

I. INTRODUCTION	1
II. EXPERIENCE AND QUALIFICATIONS.....	1
III. LEGAL STANDARDS USED IN MY ANALYSIS.....	3
A. Prior Art.....	3
B. Person of Ordinary Skill In The Art.....	3
C. Anticipation	4
D. Obviousness.....	5
IV. THE '929 PATENT.....	7
A. The Alleged Invention.....	7
B. Challenged Claims	7
C. Claim Construction.....	9
V. BACKGROUND	9
VI. PRIOR ART	10
A. Drach (Ex. 1003).....	11
B. Zeldis (Ex. 1004).....	12
C. Querfeld (Ex. 1005).....	14
D. Celgene Press Release (Ex. 1006).....	15
VII. OBVIOUSNESS.....	16
A. Claims 1-4, 8-9, 15 and 20 Would Have Been Obvious Based on Drach in View of Zeldis	16

a. Claim 1 Would Have Been Obvious	16
b. Claim 2 Would Have Been Obvious	22
c. Claim 3 Would Have Been Obvious	23
d. Claim 4 Would Have Been Obvious	24
e. Claim 8 Would Have Been Obvious	25
f. Claim 9 Would Have Been Obvious.....	25
g. Claim 15 Would Have Been Obvious	26
h. Claim 20 Would Have Been Obvious	26
B. Claims 4 and 20 Would Have Been Obvious.....	27
C. Lack of Secondary Considerations.....	28
a. The Efficacy of Lenalidomide in Relapsed and/or Refractory MCL Patients Would Have Been Expected	28
b. The Need for Treatments of Relapsed and/or Refractory MCL Is Still Unmet.....	29
VIII. ANTICIPATION.....	30
A. Claims 1-4, 8-9, 15 And 20 Are Anticipated by the Celgene Press Release 30	
a. Claim 1 Is Anticipated.....	30
b. Claim 2 Is Anticipated.....	32
c. Claim 3 Is Anticipated	32
d. Claim 4 Is Anticipated.....	33
e. Claim 8 Is Anticipated.....	33

f. Claim 9 Is Anticipated33

g. Claim 15 Is Anticipated.....34

h. Claim 20 Is Anticipated.....34

IX. CONCLUSION35

LIST OF EXHIBITS CITED

Exhibit No.	Description
1001	Zeldis, J.B. et al., U.S. Patent No. 8,741,929, “Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas” (“the ’929 patent”)
1003	Drach, J. et al., “Treatment of Mantle Cell Lymphoma: Targeting the Microenvironment,” <i>Expert Review of Anticancer Therapy</i> , 5:477-85 (2005) (“Drach”)
1004	U.S. Patent Application Publication No. 2004/0029832 (“Zeldis”)
1005	Querfeld, C. et al., “Preliminary Results of a Phase II Study of CC-5013 (Lenalidomide, Revlimid®) in Patients with Cutaneous T-Cell Lymphoma,” <i>Blood</i> , 106:3351 (2005) (“Querfeld”)
1006	Celgene Press Release, Celgene Corp., Revlimid® (Lenalidomide) Clinical Results in Non-Hodgkins Lymphoma Presented at the 11 th Congress of the European Hematology Association (June 19, 2006) (“Celgene Press Release”)
1008	U.S. Application No. 12/621,502, Declaration of Lei Zhang, M.D. Pursuant to 37 C.F.R. §1.132 (dated Dec. 18, 2013)
1010	Harris, N.L. et al., “World Health Organization Classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting,” <i>J. Clin. Oncol.</i> 17:3835-49 (1999) (“Harris”)
1011	Bartlett, J.B. et al, “The evolution of thalidomide and its ImiD derivatives as anticancer agents,” <i>Nature Rev. Cancer</i> 4:314-22 (2004) (“Bartlett”)
1012	Wiernik, P.H. [sic] et al., “Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma [abstract],” in 11 th Congress of the European Hematology Association, June 15-18, 2006, Amsterdam, the Netherlands, Abstract No. 706 (“Wiernik”)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.